Jacobs Levy Equity Management Inc. Buys 226,466 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Jacobs Levy Equity Management Inc. boosted its stake in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 204.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 337,265 shares of the company's stock after acquiring an additional 226,466 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.43% of Tenaya Therapeutics worth $651,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in TNYA. The Manufacturers Life Insurance Company raised its position in shares of Tenaya Therapeutics by 43.2% in the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company's stock valued at $72,000 after buying an additional 7,000 shares in the last quarter. Algert Global LLC bought a new stake in shares of Tenaya Therapeutics during the 2nd quarter worth $74,000. SG Americas Securities LLC purchased a new position in Tenaya Therapeutics during the 3rd quarter valued at about $49,000. Panagora Asset Management Inc. bought a new stake in Tenaya Therapeutics during the second quarter worth about $164,000. Finally, Walleye Capital LLC purchased a new stake in Tenaya Therapeutics in the third quarter worth approximately $134,000. 90.54% of the stock is owned by institutional investors.

Tenaya Therapeutics Stock Performance

Tenaya Therapeutics stock traded up $0.20 during trading on Tuesday, reaching $3.78. 5,042,369 shares of the company's stock were exchanged, compared to its average volume of 1,108,053. The firm has a market cap of $299.46 million, a price-to-earnings ratio of -2.63 and a beta of 2.71. The company's 50-day moving average is $2.32 and its two-hundred day moving average is $2.79. Tenaya Therapeutics, Inc. has a 52-week low of $1.61 and a 52-week high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.07. Analysts anticipate that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on TNYA. Piper Sandler reaffirmed an "overweight" rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Leerink Partners reaffirmed an "outperform" rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a report on Monday, November 25th. Chardan Capital lowered their price target on Tenaya Therapeutics from $20.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, November 7th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $17.33.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.